Sept 21 (Reuters) – Novo Nordisk said on Monday its next-generation experimental drug had achieved an estimated average weight loss of 12.4% in a late-stage trial and that it was superior to Eli
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
(Updates after Yu wins second gold at Asian Games) TOKYO, Sept 21 (Reuters) - China's…
By Fernando Kallas MADRID, Sept 21 (Reuters) - Spain coach Luis de la Fuente has…
Sept 21 (Reuters) - Smart ring maker Oura said on Monday it is seeking to…
By Kate Abnett BRUSSELS, Sept 21 (Reuters) - The European Commission proposed rules on Monday…
CHINA CENTRAL BANK HOLDS MEETING WITH FOREIGN FINANCIAL INSTITUTIONS - STATEMENT (The article has been…
Sep 21 (OPTA) - Standings for the Premier League on Monday P W D L…